Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.55 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | FAP | Q12884 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13472178 | 0.86 | DPP4 (0.51) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL214373 | 0.84 | DPP4 (0.67) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL29558815 | 0.84 | DPP4 (0.67) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL24713208 | 0.82 | DPP4 (0.50) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL15367709 | 0.81 | DPP4 (0.66) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL6877160 | 0.80 | DPP4 (0.83) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL16230987 | 0.80 | DPP4 (0.83) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL13637938 | 0.80 | DPP4 (0.50) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL16231055 | 0.80 | DPP4 (0.83) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL11948346 | 0.76 | DPP4 (0.60) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9587229-B2 | Immobilized transaminases and process for making and using immobilized transaminase | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9550982-B2 | Transaminase biocatalysts | CODEXIS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160264948-A1 | TRANSAMINASE BIOCATALYSTS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2016-09-15 | — | — | US | disclosed |
| US-9353355-B2 | Transaminase biocatalysts | CODEXIS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150329838-A1 | TRANSAMINASE BIOCATALYSTS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-11-19 | — | — | US | disclosed |
| US-9133445-B2 | Transaminase biocatalysts | CODEXIS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-8969558-B2 | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof | DR. REDDY'S LABORATORIES LIMITED (IN) | 2015-03-03 | — | — | US | disclosed |
| US-20150037869-A1 | TRANSAMINASE BIOCATALYSTS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-02-05 | — | — | US | disclosed |
| US-8889380-B2 | Transaminase biocatalysts | CODEXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140128607-A1 | PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | DR. REDDY'S LABORATORIES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20130289276-A1 | PROCESS FOR PREPARING AN INTERMEDIATE OF SITAGLIPTIN VIA ENZYMATIC CONVERSION | CADILA HEALTHCARE LIMITED (IN) | 2013-10-31 | — | — | US | disclosed |
| US-7612072-B2 | Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | MERCK & CO., INC. (US) | 2009-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128607-A1 | PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | DPP4, DPP9, DPP3 | DPP4 1/4885DPP8 5/4885DPP9 2/4885 |
| US-20130289276-A1 | PROCESS FOR PREPARING AN INTERMEDIATE OF SITAGLIPTIN VIA ENZYMATIC CONVERSION | DPP4, DPP7, DPP9 | DPP4 1/4885DPP8 7/4885DPP9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.